-
1
-
-
0033618504
-
Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA
-
Bauer, S., V. Groh, J. Wu, A. Steinle, J. H. Phillips, L. L. Lanier, and T. Spies. Activation of NK cells and T cells by NKG2D, a receptor for stressinducible MICA. Science 285: 727-729.
-
Science
, vol.285
, pp. 727-729
-
-
Bauer, S.1
Groh, V.2
Wu, J.3
Steinle, A.4
Phillips, J.H.5
Lanier, L.L.6
Spies, T.7
-
2
-
-
0033618624
-
An activating immunoreceptor complex formed by NKG2D and DAP10
-
Wu, J., Y. Song, A. B. Bakker, S. Bauer, T. Spies, L. L. Lanier, and J. H. Phillips. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285: 730-732.
-
Science
, vol.285
, pp. 730-732
-
-
Wu, J.1
Song, Y.2
Bakker, A.B.3
Bauer, S.4
Spies, T.5
Lanier, L.L.6
Phillips, J.H.7
-
3
-
-
29444455376
-
NKG2D in NK and T cell-mediated immunity
-
DOI 10.1007/s10875-005-8786-4
-
Ogasawara, K., and L. L. Lanier. 2005. NKG2D in NK and T cell-mediated immunity. J. Clin. Immunol. 25: 534-540. (Pubitemid 43011745)
-
(2005)
Journal of Clinical Immunology
, vol.25
, Issue.6
, pp. 534-540
-
-
Ogasawara, K.1
Lanier, L.L.2
-
4
-
-
0029861713
-
Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium
-
Groh, V., S. Bahram, S. Bauer, A. Herman, M. Beauchamp, and T. Spies. 1996. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450.
-
(1996)
Proc. Natl. Acad. Sci. USA
, vol.93
, pp. 12445-12450
-
-
Groh, V.1
Bahram, S.2
Bauer, S.3
Herman, A.4
Beauchamp, M.5
Spies, T.6
-
5
-
-
24144443517
-
The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor
-
DOI 10.1038/nature03884
-
Gasser, S., S. Orsulic, E. J. Brown, and D. H. Raulet. 2005. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436: 1186-1190. (Pubitemid 41232299)
-
(2005)
Nature
, vol.436
, Issue.7054
, pp. 1186-1190
-
-
Gasser, S.1
Orsulic, S.2
Brown, E.J.3
Raulet, D.H.4
-
6
-
-
33645767415
-
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia
-
Boissel, N., D. Rea, V. Tieng, N. Dulphy, M. Brun, J. M. Cayuela, P. Rousselot, R. Tamouza, P. Le Bouteiller, F. X. Mahon, et al. 2006. BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia. J. Immunol. 176: 5108-5116.
-
(2006)
J. Immunol.
, vol.176
, pp. 5108-5116
-
-
Boissel, N.1
Rea, D.2
Tieng, V.3
Dulphy, N.4
Brun, M.5
Cayuela, J.M.6
Rousselot, P.7
Tamouza, R.8
Le Bouteiller, P.9
Mahon, F.X.10
-
7
-
-
33750694590
-
Activation, coactivation, and costimulation of resting human natural killer cells
-
DOI 10.1111/j.1600-065X.2006.00457.x
-
Bryceson, Y. T., M. E. March, H. G. Ljunggren, and E. O. Long. 2006. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214: 73-91. (Pubitemid 44707903)
-
(2006)
Immunological Reviews
, vol.214
, Issue.1
, pp. 73-91
-
-
Bryceson, Y.T.1
March, M.E.2
Ljunggren, H.-G.3
Long, E.O.4
-
8
-
-
0035949563
-
Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo
-
DOI 10.1073/pnas.201238598
-
Cerwenka, A., J. L. Baron, and L. L. Lanier. 2001. Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc. Natl. Acad. Sci. USA 98: 11521-11526. (Pubitemid 32928761)
-
(2001)
Proceedings of the National Academy of Sciences of the United States of America
, vol.98
, Issue.20
, pp. 11521-11526
-
-
Cerwenka, A.1
Baron, J.L.2
Lanier, L.L.3
-
9
-
-
2342591455
-
The discovery of receptor tyrosine kinases: Targets for cancer therapy
-
Gschwind, A., O. M. Fischer, and A. Ullrich. 2004. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat. Rev. Cancer 4: 361-370. (Pubitemid 38579482)
-
(2004)
Nature Reviews Cancer
, vol.4
, Issue.5
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
10
-
-
0028168569
-
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity
-
Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway, III. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl. Acad. Sci. USA 91: 8132-8136.
-
Proc. Natl. Acad. Sci. USA
, vol.91
, pp. 8132-8136
-
-
Guy, P.M.1
Platko, J.V.2
Cantley, L.C.3
Cerione, R.A.4
Carraway III, K.L.5
-
11
-
-
0028358856
-
Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin
-
Sliwkowski, M. X., G. Schaefer, R. W. Akita, J. A. Lofgren, V. D. Fitzpatrick, A. Nuijens, B. M. Fendly, R. A. Cerione, R. L. Vandlen, and K. L. Carraway, III. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269: 14661-14665.
-
J. Biol. Chem.
, vol.269
, pp. 14661-14665
-
-
Sliwkowski, M.X.1
Schaefer, G.2
Akita, R.W.3
Lofgren, J.A.4
Fitzpatrick, V.D.5
Nuijens, A.6
Fendly, B.M.7
Cerione, R.A.8
Vandlen, R.L.9
Carraway III, K.L.10
-
12
-
-
2142843806
-
Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
-
Pinkas-Kramarski, R., L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, L. Klapper, S. Lavi, R. Seger, B. J. Ratzkin, M. Sela, and Y. Yarden. 1996. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15: 2452-2467.
-
(1996)
EMBO J.
, vol.15
, pp. 2452-2467
-
-
Pinkas-Kramarski, R.1
Soussan, L.2
Waterman, H.3
Levkowitz, G.4
Alroy, I.5
Klapper, L.6
Lavi, S.7
Seger, R.8
Ratzkin, B.J.9
Sela, M.10
Yarden, Y.11
-
13
-
-
0029814271
-
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
-
Tzahar, E., H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, S. Lavi, B. J. Ratzkin, and Y. Yarden. 1996. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/ neuregulin and epidermal growth factor. Mol. Cell. Biol. 16: 5276-5287. (Pubitemid 26315047)
-
(1996)
Molecular and Cellular Biology
, vol.16
, Issue.10
, pp. 5276-5287
-
-
Tzahar, E.1
Waterman, H.2
Chen, X.3
Levkowitz, G.4
Karunagaran, D.5
Lavi, S.6
Ratzkin, B.J.7
Yarden, Y.8
-
14
-
-
0042307325
-
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
-
DOI 10.1073/pnas.1537685100
-
Holbro, T., R. R. Beerli, F. Maurer, M. Koziczak, C. F. Barbas, III, and N. E. Hynes. 2003. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100: 8933-8938. (Pubitemid 36899201)
-
(2003)
Proceedings of the National Academy of Sciences of the United States of America
, vol.100
, Issue.15
, pp. 8933-8938
-
-
Holbro, T.1
Beerli, R.R.2
Maurer, F.3
Koziczak, M.4
Barbas III, C.F.5
Hynes, N.E.6
-
15
-
-
10744230127
-
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
-
Burgess, A. W., H. S. Cho, C. Eigenbrot, K. M. Ferguson, T. P. Garrett, D. J. Leahy, M. A. Lemmon, M. X. Sliwkowski, C. W. Ward, and S. Yokoyama. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12: 541-552.
-
Mol. Cell
, vol.12
, pp. 541-552
-
-
Burgess, A.W.1
Cho, H.S.2
Eigenbrot, C.3
Ferguson, K.M.4
Garrett, T.P.5
Leahy, D.J.6
Lemmon, M.A.7
Sliwkowski, M.X.8
Ward, C.W.9
Yokoyama, S.10
-
16
-
-
18344390418
-
ERBB receptors and cancer: The complexity of targeted inhibitors
-
DOI 10.1038/nrc1609
-
Hynes, N. E., and H. A. Lane. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 5: 341-354. (Pubitemid 40637826)
-
(2005)
Nature Reviews Cancer
, vol.5
, Issue.5
, pp. 341-354
-
-
Hynes, N.E.1
Lane, H.A.2
-
18
-
-
16244409820
-
Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549
-
DOI 10.1038/sj.onc.1208381
-
Sithanandam, G., L. W. Fornwald, J. Fields, and L. M. Anderson. 2005. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene 24: 1847-1859. (Pubitemid 40462787)
-
(2005)
Oncogene
, vol.24
, Issue.11
, pp. 1847-1859
-
-
Sithanandam, G.1
Fornwald, L.W.2
Fields, J.3
Anderson, L.M.4
-
19
-
-
0024360141
-
HER-2/neu oncogene protein and prognosis in breast cancer
-
Tandon, A. K., G. M. Clark, G. C. Chamness, A. Ullrich, and W. L. McGuire. HER-2/neu oncogene protein and prognosis in breast cancer. J. Clin. Oncol. 7: 1120-1128.
-
J. Clin. Oncol.
, vol.7
, pp. 1120-1128
-
-
Tandon, A.K.1
Clark, G.M.2
Chamness, G.C.3
Ullrich, A.4
McGuire, W.L.5
-
20
-
-
0038575385
-
Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer
-
Witton, C. J., J. R. Reeves, J. J. Going, T. G. Cooke, and J. M. Bartlett. 2003. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J. Pathol. 200: 290-297.
-
(2003)
J. Pathol.
, vol.200
, pp. 290-297
-
-
Witton, C.J.1
Reeves, J.R.2
Going, J.J.3
Cooke, T.G.4
Bartlett, J.M.5
-
21
-
-
0031406620
-
c-erbB-3 protein expression in ductal carcinoma in situ of the breast
-
DOI 10.1016/S0959-8049(97)00244-X, PII S095980499700244X
-
Bobrow, L. G., R. R. Millis, L. C. Happerfield, and W. J. Gullick. 1997. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur. J. Cancer 33: 1846-1850. (Pubitemid 28129215)
-
(1997)
European Journal of Cancer
, vol.33
, Issue.11
, pp. 1846-1850
-
-
Bobrow, L.G.1
Millis, R.R.2
Happerfield, L.C.3
Gullick, W.J.4
-
22
-
-
0029665946
-
C-erbB-3 in human breast carcinoma: Expression and relation to prognosis and established prognostic indicators
-
Travis, A., S. E. Pinder, J. F. Robertson, J. A. Bell, P. Wencyk, W. J. Gullick, R. I. Nicholson, D. N. Poller, R. W. Blamey, C. W. Elston, and I. O. Ellis. 1996. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br. J. Cancer 74: 229-233.
-
(1996)
Br. J. Cancer
, vol.74
, pp. 229-233
-
-
Travis, A.1
Pinder, S.E.2
Robertson, J.F.3
Bell, J.A.4
Wencyk, P.5
Gullick, W.J.6
Nicholson, R.I.7
Poller, D.N.8
Blamey, R.W.9
Elston, C.W.10
Ellis, I.O.11
-
23
-
-
0028169757
-
C-erbB-3 protein expression in human breast cancer: Comparison with other tumour variables and survival
-
Quinn, C. M., J. L. Ostrowski, S. A. Lane, D. P. Loney, J. Teasdale, and F. A. Benson. 1994. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 25: 247-252.
-
(1994)
Histopathology
, vol.25
, pp. 247-252
-
-
Quinn, C.M.1
Ostrowski, J.L.2
Lane, S.A.3
Loney, D.P.4
Teasdale, J.5
Benson, F.A.6
-
24
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon, D. J., B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783-792. (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
25
-
-
79952041937
-
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4-year follow-up of a randomised controlled trial
-
Herceptin Adjuvant (HERA) Trial Study Team
-
Gianni, L., U. Dafni, R. D. Gelber, E. Azambuja, S. Muehlbauer, A. Goldhirsch, M. Untch, I. Smith, J. Baselga, C. Jackisch, et al; Herceptin Adjuvant (HERA) Trial Study Team. 2011. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 12: 236-244.
-
(2011)
Lancet Oncol.
, vol.12
, pp. 236-244
-
-
Gianni, L.1
Dafni, U.2
Gelber, R.D.3
Azambuja, E.4
Muehlbauer, S.5
Goldhirsch, A.6
Untch, M.7
Smith, I.8
Baselga, J.9
Jackisch, C.10
-
26
-
-
67649472398
-
Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3
-
Baselga, J., and S. M. Swain. 2009. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 9: 463-475.
-
(2009)
Nat. Rev. Cancer
, vol.9
, pp. 463-475
-
-
Baselga, J.1
Swain, S.M.2
-
27
-
-
77950216941
-
An ErbB3 antibody, MM- 121, is active in cancers with ligand-dependent activation
-
Schoeberl, B., A. C. Faber, D. Li, M. C. Liang, K. Crosby, M. Onsum, O. Burenkova, E. Pace, Z. Walton, L. Nie, et al. 2010. An ErbB3 antibody, MM- 121, is active in cancers with ligand-dependent activation. Cancer Res. 70: 2485-2494.
-
(2010)
Cancer Res.
, vol.70
, pp. 2485-2494
-
-
Schoeberl, B.1
Faber, A.C.2
Li, D.3
Liang, M.C.4
Crosby, K.5
Onsum, M.6
Burenkova, O.7
Pace, E.8
Walton, Z.9
Nie, L.10
-
28
-
-
0031870766
-
Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice
-
DOI 10.1002/(SICI)1097-0215(19980911)77:6<937::AID-IJC24>3.0.CO;2-X
-
Lollini, P. L., G. Nicoletti, L. Landuzzi, C. De Giovanni, I. Rossi, E. Di Carlo, P. Musiani, W. J. Muller, and P. Nanni. 1998. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer 77: 937-941. (Pubitemid 28378147)
-
(1998)
International Journal of Cancer
, vol.77
, Issue.6
, pp. 937-941
-
-
Lollini, P.-L.1
Nicoletti, G.2
Landuzzi, L.3
De Giovanni, C.4
Rossi, I.5
Di, C.E.6
Musiani, P.7
Muller, W.J.8
Nanni, P.9
-
29
-
-
1642535582
-
HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway
-
DOI 10.1158/0008-5472.CAN-2522-2
-
Herrmann, F., H. A. Lehr, I. Drexler, G. Sutter, J. Hengstler, U. Wollscheid, and B. Seliger. 2004. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 64: 215-220. (Pubitemid 38114101)
-
(2004)
Cancer Research
, vol.64
, Issue.1
, pp. 215-220
-
-
Herrmann, F.1
Lehr, H.-A.2
Drexler, I.3
Sutter, G.4
Hengstler, J.5
Wollscheid, U.6
Seliger, B.7
-
30
-
-
0344825125
-
Small interfering RNA (siRNA) inhibits the expression of the Her2/Neu gene, upregulates HLA class I and induces apoptosis of Her2/Neu positive tumor cell lines
-
DOI 10.1002/ijc.11497
-
Choudhury, A., J. Charo, S. K. Parapuram, R. C. Hunt, D. M. Hunt, B. Seliger, and R. Kiessling. 2004. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/ neu positive tumor cell lines. Int. J. Cancer 108: 71-77. (Pubitemid 37444446)
-
(2004)
International Journal of Cancer
, vol.108
, Issue.1
, pp. 71-77
-
-
Choudhury, A.1
Charo, J.2
Parapuram, S.K.3
Hunt, R.C.4
Hunt, D.M.5
Seliger, B.6
Kiessling, R.7
-
31
-
-
61349186956
-
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice
-
Vertuani, S., C. Triulzi, A. K. Roos, J. Charo, H. Norell, F. Lemonnier, P. Pisa, B. Seliger, and R. Kiessling. 2009. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol. Immunother. 58: 653-664.
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, pp. 653-664
-
-
Vertuani, S.1
Triulzi, C.2
Roos, A.K.3
Charo, J.4
Norell, H.5
Lemonnier, F.6
Pisa, P.7
Seliger, B.8
Kiessling, R.9
-
32
-
-
78649581349
-
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
-
Mimura, K., T. Ando, I. Poschke, D. Mougiakakos, C. C. Johansson, J. Ichikawa, R. Okita, M. I. Nishimura, D. Handke, N. Krug, et al. 2011. T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2. Int. J. Cancer 128: 390-401.
-
(2011)
Int. J. Cancer
, vol.128
, pp. 390-401
-
-
Mimura, K.1
Ando, T.2
Poschke, I.3
Mougiakakos, D.4
Johansson, C.C.5
Ichikawa, J.6
Okita, R.7
Nishimura, M.I.8
Handke, D.9
Krug, N.10
-
33
-
-
0022616253
-
Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
-
Kärre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678. (Pubitemid 16119452)
-
(1986)
Nature
, vol.319
, Issue.6055
, pp. 675-678
-
-
Karre, K.1
Ljunggren, H.G.2
Piontek, G.3
Kiessling, R.4
-
34
-
-
77956642196
-
Natural killer cell education and tolerance
-
Orr, M. T., and L. L. Lanier. 2010. Natural killer cell education and tolerance. Cell 142: 847-856.
-
(2010)
Cell
, vol.142
, pp. 847-856
-
-
Orr, M.T.1
Lanier, L.L.2
-
35
-
-
0344745168
-
Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity
-
DOI 10.1073/pnas.83.15.5620
-
Torsteinsdottir, S., M. G. Masucci, B. Ehlin-Henriksson, C. Brautbar, H. Ben Bassat, G. Klein, and E. Klein. 1986. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc. Natl. Acad. Sci. USA 83: 5620-5624. (Pubitemid 16001269)
-
(1986)
Proceedings of the National Academy of Sciences of the United States of America
, vol.83
, Issue.15
, pp. 5620-5624
-
-
Torsteinsdottir, S.1
Masucci, M.G.2
Ehlin-Henriksson, B.3
-
36
-
-
0037068741
-
Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
-
Xia, W., R. J. Mullin, B. R. Keith, L. H. Liu, H. Ma, D. W. Rusnak, G. Owens, K. J. Alligood, and N. L. Spector. 2002. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263.
-
(2002)
Oncogene
, vol.21
, pp. 6255-6263
-
-
Xia, W.1
Mullin, R.J.2
Keith, B.R.3
Liu, L.H.4
Ma, H.5
Rusnak, D.W.6
Owens, G.7
Alligood, K.J.8
Spector, N.L.9
-
37
-
-
16344363218
-
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth
-
DOI 10.1158/1078-0432.CCR-04-1158
-
Gregory, C. W., Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp, III. 2005. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin. Cancer Res. 11: 1704-1712. (Pubitemid 40471831)
-
(2005)
Clinical Cancer Research
, vol.11
, Issue.5
, pp. 1704-1712
-
-
Gregory, C.W.1
Whang, Y.E.2
McCall, W.3
Fei, X.4
Liu, Y.5
Ponguta, L.A.6
French, F.S.7
Wilson, E.M.8
Earp III, H.S.9
-
38
-
-
0028170210
-
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran- 4-one (LY294002)
-
Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. 1994. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1- benzopyran- 4-one (LY294002). J. Biol. Chem. 269: 5241-5248.
-
(1994)
J. Biol. Chem.
, vol.269
, pp. 5241-5248
-
-
Vlahos, C.J.1
Matter, W.F.2
Hui, K.Y.3
Brown, R.F.4
-
39
-
-
0029034774
-
Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor
-
Pang, L., T. Sawada, S. J. Decker, and A. R. Saltiel. 1995. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J. Biol. Chem. 270: 13585-13588.
-
(1995)
J. Biol. Chem.
, vol.270
, pp. 13585-13588
-
-
Pang, L.1
Sawada, T.2
Decker, S.J.3
Saltiel, A.R.4
-
40
-
-
0029053716
-
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
-
Alimandi, M., A. Romano, M. C. Curia, R. Muraro, P. Fedi, S. A. Aaronson, P. P. Di Fiore, and M. H. Kraus. 1995. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821.
-
(1995)
Oncogene
, vol.10
, pp. 1813-1821
-
-
Alimandi, M.1
Romano, A.2
Curia, M.C.3
Muraro, R.4
Fedi, P.5
Aaronson, S.A.6
Di Fiore, P.P.7
Kraus, M.H.8
-
41
-
-
0021151237
-
Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
-
Tewey, K. M., T. C. Rowe, L. Yang, B. D. Halligan, and L. F. Liu. 1984. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226: 466-468.
-
(1984)
Science
, vol.226
, pp. 466-468
-
-
Tewey, K.M.1
Rowe, T.C.2
Yang, L.3
Halligan, B.D.4
Liu, L.F.5
-
42
-
-
11144234525
-
Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species
-
DOI 10.1074/jbc.M406879200
-
Kurz, E. U., P. Douglas, and S. P. Lees-Miller. 2004. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 279: 53272-53281. (Pubitemid 40051831)
-
(2004)
Journal of Biological Chemistry
, vol.279
, Issue.51
, pp. 53272-53281
-
-
Kurz, E.U.1
Douglas, P.2
Lees-Miller, S.P.3
-
43
-
-
65349131915
-
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype
-
Soriani, A., A. Zingoni, C. Cerboni, M. L. Iannitto, M. R. Ricciardi, V. Di Gialleonardo, M. Cippitelli, C. Fionda, M. T. Petrucci, A. Guarini, et al. 2009. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113: 3503-3511.
-
(2009)
Blood
, vol.113
, pp. 3503-3511
-
-
Soriani, A.1
Zingoni, A.2
Cerboni, C.3
Iannitto, M.L.4
Ricciardi, M.R.5
Di Gialleonardo, V.6
Cippitelli, M.7
Fionda, C.8
Petrucci, M.T.9
Guarini, A.10
-
44
-
-
0033199892
-
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
-
Sarkaria, J. N., E. C. Busby, R. S. Tibbetts, P. Roos, Y. Taya, L. M. Karnitz, and R. T. Abraham. 1999. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res. 59: 4375-4382. (Pubitemid 29418757)
-
(1999)
Cancer Research
, vol.59
, Issue.17
, pp. 4375-4382
-
-
Sarkaria, J.N.1
Busby, E.C.2
Tibbetts, R.S.3
Roos, P.4
Taya, Y.5
Karnitz, L.M.6
Abraham, R.T.7
-
45
-
-
0032513388
-
Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells
-
DOI 10.1126/science.279.5357.1737
-
Groh, V., A. Steinle, S. Bauer, and T. Spies. 1998. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279: 1737-1740. (Pubitemid 28164472)
-
(1998)
Science
, vol.279
, Issue.5357
, pp. 1737-1740
-
-
Groh, V.1
Steinle, A.2
Bauer, S.3
Spies, T.4
-
46
-
-
0028302018
-
ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
-
Soltoff, S. P., K. L. Carraway, III, S. A. Prigent, W. G. Gullick, and L. C. Cantley. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14: 3550-3558.
-
Mol. Cell. Biol.
, vol.14
, pp. 3550-3558
-
-
Soltoff, S.P.1
Carraway III, K.L.2
Prigent, S.A.3
Gullick, W.G.4
Cantley, L.C.5
-
47
-
-
33846245583
-
Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D
-
Venkataraman, G. M., D. Suciu, V. Groh, J. M. Boss, and T. Spies. 2007. Promoter region architecture and transcriptional regulation of the genes for the MHC class I-related chain A and B ligands of NKG2D. J. Immunol. 178: 961-969. (Pubitemid 46095169)
-
(2007)
Journal of Immunology
, vol.178
, Issue.2
, pp. 961-969
-
-
Venkataraman, G.M.1
Suciu, D.2
Groh, V.3
Boss, J.M.4
Spies, T.5
-
48
-
-
35148885729
-
A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer
-
DOI 10.1016/j.ccr.2007.08.030, PII S1535610807002620
-
Berns, K., H. M. Horlings, B. T. Hennessy, M. Madiredjo, E. M. Hijmans, K. Beelen, S. C. Linn, A. M. Gonzalez-Angulo, K. Stemke-Hale, M. Hauptmann, et al. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402. (Pubitemid 47539306)
-
(2007)
Cancer Cell
, vol.12
, Issue.4
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
Madiredjo, M.4
Hijmans, E.M.5
Beelen, K.6
Linn, S.C.7
Gonzalez-Angulo, A.M.8
Stemke-Hale, K.9
Hauptmann, M.10
Beijersbergen, R.L.11
Mills, G.B.12
Van De, V.M.J.13
Bernards, R.14
-
49
-
-
0036898636
-
Neuregulin expression, function, and signaling in human ovarian cancer cells
-
Gilmour, L. M., K. G. Macleod, A. McCaig, J. M. Sewell, W. J. Gullick, J. F. Smyth, and S. P. Langdon. 2002. Neuregulin expression, function, and signaling in human ovarian cancer cells. Clin. Cancer Res. 8: 3933-3942. (Pubitemid 35424788)
-
(2002)
Clinical Cancer Research
, vol.8
, Issue.12
, pp. 3933-3942
-
-
Gilmour, L.M.R.1
Macleod, K.G.2
McCaig, A.3
Sewell, J.M.4
Gullick, W.J.5
Smyth, J.F.6
Langdon, S.P.7
-
50
-
-
60149109196
-
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
-
Scaltriti, M., C. Verma, M. Guzman, J. Jimenez, J. L. Parra, K. Pedersen, D. J. Smith, S. Landolfi, S. Ramon y Cajal, J. Arribas, and J. Baselga. 2009. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28: 803-814.
-
(2009)
Oncogene
, vol.28
, pp. 803-814
-
-
Scaltriti, M.1
Verma, C.2
Guzman, M.3
Jimenez, J.4
Parra, J.L.5
Pedersen, K.6
Smith, D.J.7
Landolfi, S.8
Ramon Cajal, S.9
Arribas, J.10
Baselga, J.11
-
51
-
-
79958856696
-
Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytoxicity of EGFR- And HER2- overexpressing esophageal cancer cell lines
-
Mimura, K., K. Kono, T. Maruyama, M. Watanabe, S. Izawa, S. Shiba, Y. Mizukami, Y. Kawaguchi, M. Inoue, T. Kono, et al. 2011. Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytoxicity of EGFR- and HER2- overexpressing esophageal cancer cell lines. Int. J. Cancer 129: 2408-2416.
-
(2011)
Int. J. Cancer
, vol.129
, pp. 2408-2416
-
-
Mimura, K.1
Kono, K.2
Maruyama, T.3
Watanabe, M.4
Izawa, S.5
Shiba, S.6
Mizukami, Y.7
Kawaguchi, Y.8
Inoue, M.9
Kono, T.10
|